Stifel Financial’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Stifel Financial's CRSP Position: Q3 2026 in Review
Stifel Financial reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q3 2026, selling an estimated $259K and leaving 34,978 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.
Stifel Financial first reported a position in CRSP in Q2 2019 and has held it in 30 quarters since. The position peaked at $4.05M in Q1 2024. 502 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Stifel Financial held 34,978 shares of CRISPR Therapeutics worth $1.93M as of Q3 2026.
- Stifel Financial sold 4,794 CRISPR Therapeutics shares in Q3 2026, an estimated $259K.
- CRISPR Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q3 2026, its #2093 holding.
- Stifel Financial first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 30 quarters since.
- Stifel Financial's CRISPR Therapeutics position peaked at $4.05M in Q1 2024.
- 502 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.